N-benzyladriamycin-14-valerate (AD 198) exhibits potent anti-tumor activity on TRAF3-deficient mouse B lymphoma and human multiple myeloma

Specific deletion of TRAF3 in B lymphocytes leads to B-lymphoma development in mice

(2011) C R Moore et al.   LEUKEMIA

Two Faces of Protein Kinase Cδ: The Contrasting Roles of PKCδ in Cell Survival and Cell Death

(2011) Alakananda Basu et al.   TheScientificWorldJOURNAL

Kinetics of ERK1/2 activation determine sensitivity of acute myeloid leukaemia cells to the induction of apoptosis by the novel small molecule ingenol 3-angelate (PEP005)

(2010) Peter Hampson et al.   APOPTOSIS

The impact of MYC expression in lymphoma biology: Beyond Burkitt lymphoma

(2010) Sonali M. Smith et al.   BLOOD CELLS MOLECULES AND DISEASES

Involvement of PKC delta (PKCδ) in the resistance against different doxorubicin analogs

(2010) María Ines Díaz Bessone et al.   BREAST CANCER RESEARCH AND TREATMENT

TNF Receptor-Associated Factor 3 Is Required for T Cell-Mediated Immunity and TCR/CD28 Signaling

(2010) P. Xie et al.   JOURNAL OF IMMUNOLOGY

Protection from Doxorubicin-Induced Cardiomyopathy Using the Modified Anthracycline N-Benzyladriamycin-14-valerate (AD 198)

(2010) C. Cai et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

AP-1 Regulates Cyclin D1 and c-MYC Transcription in an AKT-Dependent Manner in Response to mTOR Inhibition: Role of AIP4/Itch-Mediated JUNB Degradation

(2010) R. Vartanian et al.   MOLECULAR CANCER RESEARCH

The Protein Kinase C Agonist PEP005 (Ingenol 3-Angelate) in the Treatment of Human Cancer: A Balance between Efficacy and Toxicity

(2010) Elisabeth Ersvaer et al.   Toxins

The protein kinase C agonist PEP005 increases NF-κB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells

(2009) Astrid Marta Olsnes et al.   BRITISH JOURNAL OF HAEMATOLOGY

Epithelial-to-Mesenchymal Transition and Resistance to Ingenol 3-Angelate, a Novel Protein Kinase C Modulator, in Colon Cancer Cells

(2009) A. Ghoul et al.   CANCER RESEARCH

Identification of Copy Number Abnormalities and Inactivating Mutations in Two Negative Regulators of Nuclear Factor- B Signaling Pathways in Waldenstrom's Macroglobulinemia

(2009) E. Braggio et al.   CANCER RESEARCH

Biallelic inactivation of TRAF3 in a subset of B-cell lymphomas with interstitial del(14)(q24.1q32.33)

(2009) I Nagel et al.   LEUKEMIA

Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells

(2008) K A Benhadji et al.   BRITISH JOURNAL OF CANCER

The anti-tumor agent, ingenol-3-angelate (PEP005), promotes the recruitment of cytotoxic neutrophils by activation of vascular endothelial cells in a PKC-δ dependent manner

(2008) Peter Hampson et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Roles of TRAF molecules in B lymphocyte function

(2008) Ping Xie et al.   CYTOKINE & GROWTH FACTOR REVIEWS

TRAF2 and TRAF3 Signal Adapters Act Cooperatively to Control the Maturation and Survival Signals Delivered to B Cells by the BAFF Receptor

(2008) Sandra Gardam et al.   IMMUNITY

MyD88 Intrinsically Regulates CD4 T-Cell Responses

(2008) S. Zhou et al.   JOURNAL OF VIROLOGY

Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells

(2008) M. Serova et al.   MOLECULAR CANCER THERAPEUTICS